A variation of the bromine substitution from 6- to 7-position converts the glycogen synthase kinase-3
![](/images/gifchars/alpha.gif)
/
![](/images/gifchars/beta2.gif)
-(GSK-3-
![](/images/gifchars/alpha.gif)
/
![](/images/gifchars/beta2.gif)
) selective inhibitor 6-bromoindirubin-3'-oxime (6BIO) to a potent inhibitor of Aurora B and Ckinases. The novel indirubin analogue 7-bromoindirubin-3'-oxime (7BIO) demonstrated unexpected selectivityagainst these two kinases since the homologous kinase Aurora A was poorly inhibited. A hypothesis regardingthe 7BIO selectivity profile was stated and validated by docking, molecular dynamics, and free energyperturbation calculations. The residue (Thr217
AurA, Glu161
AurB, Glu127
AurC) located in the active site wasidentified as a major contributor to the enhanced affinity of 7BIO for Aurora B and C versus Aurora A.Furthermore, the docking events of 7BIO and several of its analogues were approached by quantitativemodels based on semiempirical scoring functions. In the course of model construction and optimization, anumber of important factors influencing the quality of each model like the application of force constraintsor the sampling method were determined. Among these factors, the presence and treatment of structurallyimportant water molecules had a pronounced impact on the quality of each model. The final model wasvalidated by use of free energy perturbation calculations.